Revealing actionable biology with multiplex immunofluorescence
Ultivue seeks to make the promise of immuno-therapy a reality for every patient through rapid, precision profiling of tumor biology.
Multiplexing now gives you the power to visualize several biomarkers at once, enabling researchers to quickly elucidate the complex phenotypes of the tumor immune microenvironment (TiME) and advance research discoveries.
Reduce TAT in the lab by developing tailored optimized assays that can be applied to a broad range of cancer types and indications to characterize immune contexture.
CD3, Granzyme B,
Cytotoxic T-cell mediated melanoma tumor cell death. In comparison to the limited information from single stain IHC (Left), Multiplexed Immunofluorescence (mIF) can capture an actionable biological event affording disease insight with spatial resolution. Here T cells demonstrate an immune response by recognizing and preparing to kill neighboring tumor cells: CD3-labeled T cells are seen releasing GrzB near SOX-10 labeled tumor cells.
Designed with translational researchers and pathologists in mind.
CD8, CD68, PD-L1, PanCK, DAPI
Co-registered stacked image of mIF
Whole Slide Scan ROI
Same slide H&E compatible
Rapid assay development
Fully customizable biomarkers
Uncover complex phenotypes
Advanced image analysis
Don’t go it alone: leveraging partnerships
Ultivue and its valued partners have established a seamless workflow integrating validated antibodies, state of the art chemistry and advanced analytics to drive personalized medicine.
With Ultivue, you know you’re getting the industry’s best at every step.
Ultivue is making an impact
Check out our catalogue of peer-reviewed publications and scientific presentations